Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lucid Diagnostics Inc. (LUCD : NSDQ)

• Company Description    Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK. Number of Employees: 72

• Price / Volume Information    Yesterday's Closing Price: $1.21 Daily Weekly Monthly 20 Day Moving Average: 1,218,364 shares Shares Outstanding: 133.48 (millions) Market Capitalization: $161.51 (millions) Beta: 1.19 52 Week High: $1.80 52 Week Low: $0.75 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 18.63% 16.46% 12 Week 23.37% 14.35% Year To Date 47.80% 26.36%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 360 MADISON AVENUE 25TH FLOOR - NEW YORK,NY 10017 USA ph: 917-813-1828 fax: - mjr@pavmed.com http://www.luciddx.com

• General Corporate Information    Officers Lishan Aklog - Chief Executive Officer & Chairman Stanley N. Lapidus - Vice Chairman & Director Dennis M. McGrath - Chief Financial Officer Debra J. White - Director James L. Cox - Director Peer Information Lucid Diagnostics Inc. (ABMD) Lucid Diagnostics Inc. (DMDS) Lucid Diagnostics Inc. (CPWY.) Lucid Diagnostics Inc. (EQUR) Lucid Diagnostics Inc. (ECIA) Lucid Diagnostics Inc. (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 54948X109 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 133.48 Most Recent Split Date: (:1) Beta: 1.19 Market Capitalization: $161.51 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.39 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 37.04 EPS Growth vs. Year Ago Period: 52.17% vs. Previous Quarter: 35.29% Sales Growth vs. Year Ago Period: 19.16% vs. Previous Quarter: 40.46% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - -120.43 03/31/25 - -124.27 Current Ratio 09/30/25 - - 06/30/25 - 1.15 03/31/25 - 0.75 Quick Ratio 09/30/25 - - 06/30/25 - 1.13 03/31/25 - 0.74 Operating Margin 09/30/25 - - 06/30/25 - -861.63 03/31/25 - -895.06 Net Margin 09/30/25 - - 06/30/25 - -1,476.35 03/31/25 - -1,699.86 Pre-Tax Margin 09/30/25 - - 06/30/25 - -1,267.41 03/31/25 - -1,481.55 Book Value 09/30/25 - - 06/30/25 - -0.43 03/31/25 - -0.57 Inventory Turnover 09/30/25 - - 06/30/25 - 14.02 03/31/25 - 12.96 Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - -

Powered by Zacks Investment Research ©